Newly renamed Patient-Centered Evidence Consortium expands focus to advance the science and impact of patient-centered evidence in drug development.Continue reading
Author Archive: Roxan Olivas
C-Path’s International Neonatal Consortium Launches Groundbreaking Neonatal Lab Values GUI Tool to Standardize Reference Ranges in Neonatal Trials
TUCSON, Ariz., November 2025 — Critical Path Institute’s® (C-Path) International Neonatal Consortium (INC) today announced the public launch of its Neonatal Laboratory Values Graphical User Interface (Neo-LV) Tool, a first-of-its-kind platform designed to harmonize and standardize laboratory reference ranges in neonatal research and clinical trials.Continue reading
FDA Qualifies C-Path Biomarker GLDH to Detect Liver Injury in Clinical Trials
C-Path’s Predictive Safety Testing Consortium led effort to qualify liver-specific biomarker to improve safety monitoring in those with muscle disease.Continue reading
C-Path’s Disease Modeling Coalition Begins Global Pediatric IBD Work from European Hub
AMSTERDAM, October 16, 2025 — Critical Path Institute® (C-Path) today announced the official launch of the Critical Path Disease Modeling Coalition (CP-DMC) on pediatric inflammatory bowel disease (pIBD).Continue reading
Critical Path Institute to be Honored with Reagan-Udall Foundation Innovation Award
Award honors regulatory science advances with measurable public health impact; ceremony December 9, 2025, Willard InterContinental, Washington, D.C.Continue reading
C-Path Names Colin Hill to Board of Directors
TUCSON, Ariz., Sept. 30, 2025 — Critical Path Institute® (C-Path) today announced the election of Colin Hill, M.S., to its Board of Directors. Hill brings deep experience at the intersection of artificial intelligence, drug development, and translational acceleration. The appointment will further strengthen C-Path’s Board of Directors’ commitment to provide optimal strategic support to the organization’s growth in advancing drug development through collaboration.Continue reading
C-Path Concludes 2025 Global Impact Conference with Progress Across Rare Diseases, Neurology and Pediatrics
Global regulators, industry leaders, scientists, and patient advocates set near-term commitments on early interception, trial modernization, and patient-first evidence.Continue reading
C-Path’s Translational Therapeutics Accelerator Marks Record Year with Seven BRIDGe Awards Advancing Potential Therapies Across Cancer, Infectious Disease, Neurology and Immunology
Program launched in 2022 has grown into a global pipeline partner for academic teams, awarding approximately $2.48 million in 2025 to projects in the U.S., Europe and AustraliaContinue reading
Join Global Leaders in Shaping the Future of Drug Development at C-Path’s 2025 Global Impact Conference
Every Stage, Every Step: Transforming Lives Through Optimized Drug DevelopmentContinue reading
Critical Path Institute Appoints Dr. Aoife Brennan to Board of Directors
TUCSON, Ariz., July 16, 2025 — Critical Path Institute® (C-Path) today announced the appointment of Aoife Brennan, M.D., to its Board of Directors. Dr. Brennan brings extensive experience in biopharmaceutical leadership, clinical development, and regulatory strategy to C-Path’s growing efforts to advance global drug development and data-driven science.Continue reading